14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MLYS vs ZLAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Mineralys Therapeutics, Inc. (MLYS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MLYS carries a Unified Composite Score of 58.9/100 (HOLD) at $14.74 (N/M Forward P/E, 0.0% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin).
Technical & Structure Timing Caution: MLYS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLYS vs ZLAB. Trailing 12-month operating profitability (MLYS 0.0% vs ZLAB -63.0%) and valuation multiples (MLYS N/M vs ZLAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment63.6% of Rev ($281M)
90D Engineering Disclosures0 Published
Investor FAQ MLYS vs ZLAB Key Questions & Quantitative Answers
As of Nov 16, 2026, Mineralys Therapeutics, Inc. (MLYS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MLYS carries a Unified Composite Score of 58.9/100 (HOLD) at $14.74 (N/M Forward P/E, 0.0% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin). Technical & Structure Timing Caution: MLYS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZLAB leads the Growth & Scale pillar: MLYS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ZLAB at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin). On trailing 12-month operating scale, MLYS generates N/A in USD-normalized revenue versus $442M for ZLAB. In operating R&D and SG&A reinvestment, MLYS deploys N/A (0 90-day corporate R&D disclosures) versus 63.6% of Rev ($281M) (0 disclosures) for ZLAB.
ZLAB screens cheaper on headline valuation multiples. MLYS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLYS (-68.5% ROE) versus ZLAB (-30.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MLYS carries 89.9% implied volatility (39th %ile, Balanced (25th–60th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 89% Vol realized risk). By comparison, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.